Version history

{
  "session_id": "sess_SDA-2026-04-12-gap-debate-20260410-113051-5dce7651_20260412-225614",
  "round_number": 2,
  "agent_persona": "persona-skeptic",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "critique",
  "content": "\n\n# Skeptic's Critical Evaluation\n\n## Hypothesis 1: ADMA-Guided Adaptive PRMT Modulation\n\n### Strongest Specific Weakness: Biomarker-Substrate Disconnect\n\nThe hypothesis conflates systemic ADMA concentration with neuronal methylation status at critical substrates. ADMA is a byproduct of arginine methylation distributed across the entire body, while TDP-43 methylation occurs in specific subcellular compartments of neurons—cells representing a tiny fraction of total body PRMT activity. The mechanistic chain from plasma ADMA → neuronal PRMT activity → TDP-43 methylation status is unestablished.\n\n### Counter-Evidence\n\nADMA elevation in AD correlates with cardiovascular comorbidity and renal function (PMID: 16368117), not necessarily with neurodegeneration-specific methylation pathology. The observed elevation may be epiphenomenological—a marker of vascular pathology that co-occurs with AD rather than a driver of TDP-43 aggregation.\n\nFurthermore, DDAH1 transgenic mice (PMID: 14687548) show that ADMA reduction improves endothelial function,",
  "tokens_used": "262"
}